Atossa Therapeutics (ATOS) Price & Analysis
ATOS Stock Chart & Stats
- Day’s Range
- MXN 42.01 - MXN 42.01
- 52-Week Range
- MXN 31.00 - MXN 255.00
- Previous Close
- MXN 45.00
- Volume
- 25
- Average Volume (3M)
- 66
- Market Cap
- MXN 406.81M
- Enterprise Value
- -MXN 9.01M
- Total Cash (Recent Filing)
- MXN 26.09M
- Total Debt (Recent Filing)
- MXN 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.14
- Next Earnings
- Nov 16, 2026
- EPS Estimate
- -16.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
A debt-free capital structure removes refinancing obligations and interest-rate exposure, giving Atossa greater flexibility while it funds clinical development. This is particularly valuable for a clinical-stage company because capital can remain focused on research rather than debt servicing, although it does not eliminate funding needs.
Clinical Pipeline Progress
Completion of Phase 2 enrollment in EVANGELINE and progress in I-SPY2 demonstrate that Atossa is advancing its lead oncology program through meaningful development milestones. Continued execution can improve the pipeline’s strategic value and create future regulatory or partnership opportunities.
Rare-disease Optionality
The two FDA rare pediatric disease designations create a potential pathway to priority review voucher value alongside the core oncology pipeline. The CVR structure also aligns shareholders with that potential, though any proceeds depend on approval, voucher award, monetization, and distributable cash.
Bears Say
No Commercial Revenue
Atossa has no commercial product revenue, so its operations and development programs are not yet supported by recurring sales. This leaves the company dependent on external financing or future clinical and regulatory success, making the business model less resilient than a revenue-generating biotechnology company.
Worsening Losses And Cash Burn
The company remains substantially unprofitable while operating cash outflows have increased from about $21.0 million in 2024 to $35.8 million on a TTM basis. Persistent and rising burn reduces financial flexibility and increases the importance of securing capital before later-stage programs mature.
Shrinking Equity Base
The steep decline in stockholders’ equity reflects cumulative losses and ongoing cash usage, indicating that the company has consumed a substantial portion of its capital base. If this trend continues, Atossa may need additional financing, creating continued dilution and funding pressure for shareholders.
Atossa Therapeutics News
Atossa’s (Z)-Endoxifen Trial Targets Rare Childhood Puberty Disorder, Opening a New Pipeline Angle
Atossa Therapeutics, Inc. ($ATOS) announced an update on their ongoing clinical study. Atossa Therapeutics, Inc. is launching a Phase 2 study of its oral drug (Z)-endoxifen in girls with McCune-Albright
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
What is Atossa Therapeutics’s market cap?
When is Atossa Therapeutics’s upcoming earnings report date?
How were Atossa Therapeutics’s earnings last quarter?
Is Atossa Therapeutics overvalued?
Does Atossa Therapeutics pay dividends?
What is Atossa Therapeutics’s EPS estimate?
How many shares outstanding does Atossa Therapeutics have?
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Atossa Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven C. Quay
- Employees
- 16
- Website
- www.atossatherapeutics.com
- Address
- 448 NW Market Street, Seattle, WA, 98107, US
Atossa Therapeutics (ATOS) Earnings & Revenues
ATOS Earnings Call
Earnings Call SentimentPositive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.
View all MX:ATOS earnings summariesATOS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |